The FDA on Thursday expanded the U.S.-approved indications for Bristol-Myers Squibb's (NYSE:BMY) blockbuster immunotherapy ...
WARN notices filed with the state show more job cuts due in the health sector as companies look to cut costs and streamline ...
A New York federal judge has dismissed a $6.4 billion lawsuit against Bristol-Myers Squibb Co., agreeing with counsel for the ...
Bristol-Myers Squibb Company ( NYSE:BMY ) stock is about to trade ex-dividend in two days. The ex-dividend date is ...
(Reuters) - Bristol Myers Squibb won the dismissal on Monday of a $6.4 billion lawsuit claiming it cheated former Celgene ...
On Wednesday, Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $53.76 which represents a slight increase of $0.86 or 1.63% from the prior close of $52.9. The stock opened at ...
This is a big approval for the company, given that Cobenfy doesn’t have the classic side effects seen in other antipsychotic ...
A federal court in New York has reportedly dismissed a $6.4B suit against Bristol Myers Squibb (NYSE:BMY) that alleged the ...
Prime Medicine, founded by David Liu, is finding that the path of translating scientific breakthroughs to treatments is ...
Bristol-Myers Squibb (BMY) stock rises as FDA approves Cobenfy as a ovel treatment for adults with the psychiatric disorder ...
Sept 30 (Reuters) - Bristol Myers Squibb (BMY.N), opens new tab won the dismissal on Monday of a $6.4 billion lawsuit claiming it cheated former Celgene shareholders by delaying federal approval ...